GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alaunos Therapeutics
Alaunos Therapeutics is a biotech company developing cell therapies for cancer treatment. Its stock price represents a venture bet on its scientific platform. The chart reflects high volatility and the need for ongoing funding.
Share prices of companies in the market segment - Oncology cell gene therapy
Alaunos Therapeutics is an oncology company developing personalized T-cell receptor-based cell therapies for the treatment of solid tumors. We've categorized it under "Oncology: Cell Therapies." The chart below shows how the market is valuing this complex yet promising sector.
Broad Market Index - GURU.Markets
Alaunos Therapeutics is an oncology company developing personalized T-cell receptor-based cell therapy for the treatment of solid tumors. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TCRT - Daily change in the company's share price Alaunos Therapeutics
For Alaunos Therapeutics, Inc., a cell therapy company, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Alaunos Therapeutics develops T-cell therapy for solid tumors. The cell-based gene therapy sector is one of the most advanced and volatile in biotech. The chart below shows the average daily fluctuations in this industry, serving as a benchmark for evaluating the highly volatile TCRT stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Alaunos Therapeutics is a biotech company working on cell therapy. Its shares are a bet on scientific breakthroughs. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alaunos Therapeutics
For Alaunos Therapeutics, year-over-year performance is the story of its cancer cell therapy platform. Its 12-month market cap is entirely dependent on clinical trial data. Its valuation is a bet that its unique, non-viral approach to developing TCR-T therapies will succeed where others have failed.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
As an early-stage biotech company, Alaunos is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alaunos Therapeutics, a company developing personalized cancer cell therapy based on TCR-T cells, is at the forefront of oncology. Its annual market capitalization growth is a clear bet on science. The success of its platform could revolutionize the treatment of solid tumors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alaunos Therapeutics
Alaunos Therapeutics is an oncology company developing T-cell therapy. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the viability of its unique technology are the main driver.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Alaunos Therapeutics is developing personalized cell therapy for cancer based on T-cell receptors that target tumor mutations. This is a cutting-edge but complex approach. The oncology sector's timeline reflects the overall interest in cell therapy, providing the backdrop for evaluating Alaunos's high-risk but potentially revolutionary platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alaunos Therapeutics, a cancer cell therapy company, is a high-risk biotech. Its shares can soar or plummet on research news, completely ignoring the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alaunos Therapeutics
Alaunos Therapeutics, a company developing personalized cell therapy for cancer, is at the forefront of oncology. Its weekly stock price performance reflects complex scientific data, progress in clinical trials, and investor confidence in its unique treatment approach.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Alaunos Therapeutics works in cancer cell therapy using TCR-T technology. This is one of the most advanced and risky approaches in oncology. The chart clearly shows how the company's shares are waiting for breakthrough data, completely isolated from general market trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alaunos Therapeutics operates in the field of cancer cell therapy. Its shares are caught in a world of hope and disappointment in clinical trials. The chart clearly shows how its performance is completely disconnected from general market trends and driven solely by scientific developments.
Market capitalization of the company, segment and market as a whole
TCRT - Market capitalization of the company Alaunos Therapeutics
Alaunos Therapeutics' market capitalization chart reflects the complexities and risks of cell therapy development. Its extremely low valuation reflects how investors have reacted to the discontinuation of its key clinical programs. Its current market capitalization is essentially a valuation of its remaining technologies and cash.
TCRT - Share of the company's market capitalization Alaunos Therapeutics within the market segment - Oncology cell gene therapy
Alaunos Therapeutics (formerly Ziopharm Oncology) develops personalized cell therapy for cancer based on T-cell receptors. Its market share is small, but it operates at the forefront of oncology. Its market capitalization reflects both the enormous potential of its technology and the high risks and costs of development.
Market capitalization of the market segment - Oncology cell gene therapy
This chart shows the total value of the entire biotech sector specializing in cell and gene therapy. For Alaunos Therapeutics, which operates in this field, this line is a map of the future of oncology. The rising chart represents an influx of capital into technologies that promise to "teach" the immune system to recognize and destroy cancer cells.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alaunos Therapeutics is a company working in the field of cancer cell therapy. Its market capitalization, like that of many players in this field, is a reflection of its scientific platform and investors' confidence in the success of its approach.
Book value capitalization of the company, segment and market as a whole
TCRT - Book value capitalization of the company Alaunos Therapeutics
Alaunos Therapeutics (formerly Ziopharm Oncology) developed cell therapies for cancer. Its book value reflected its financial resources and scientific platform. The chart below provides a historical look at how this company's equity has changed over the course of its complex transformation and research.
TCRT - Share of the company's book capitalization Alaunos Therapeutics within the market segment - Oncology cell gene therapy
Alaunos Therapeutics is a cell therapy company. Its innovative TCR-T therapy platform requires a sophisticated infrastructure: in-house R&D centers and manufacturing facilities to create personalized cancer drugs. The chart shows the company's share of the physical infrastructure required for this area.
Market segment balance sheet capitalization - Oncology cell gene therapy
Alaunos Therapeutics is a cell therapy company. Pharmaceuticals, as the chart shows, are capital-intensive. Alaunos is a prime example. Its business requires the construction of its own highly complex and expensive laboratories and factories.
Book value of all companies included in the broad market index - GURU.Markets
Alaunos Therapeutics' assets are not drugs, but a research platform and pilot plant for developing personalized T-cell cancer therapy based on the company's proprietary approach. The book value reflects the material resources required for this complex and expensive research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alaunos Therapeutics
Alaunos Therapeutics is an oncology company focused on cell therapy. Its market value is determined by its scientific platform. Investors are betting on its ability to create personalized cancer treatments.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Alaunos Therapeutics is a biotech company focused on cancer cell therapy. Its valuation on this chart reflects both the enormous potential of this technology and the high risks and costs associated with its development and production.
Market to book capitalization ratio for the market as a whole
Alaunos Therapeutics is developing personalized cell therapy for cancer. This is at the cutting edge of science, and the company's market valuation reflects faith in its technological platform. This chart illustrates the enormous market premium that can be placed on potentially revolutionary, yet highly risky, approaches to oncology.
Debts of the company, segment and market as a whole
TCRT - Company debts Alaunos Therapeutics
Alaunos, a company developing cell therapy for cancer, has a highly capital-intensive R&D program. It relies entirely on external funding. This chart illustrates the enormous costs associated with working at the forefront of oncology, where every experiment and patient requires significant resources.
Market segment debts - Oncology cell gene therapy
Alaunos Therapeutics is a clinical-stage biotech company developing personalized cell therapy for solid tumors. Its approach is based on the use of a patient's own T cells. The chart shows how the company funds its cutting-edge, yet highly complex and expensive, immuno-oncology research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alaunos Therapeutics
Alaunos Therapeutics (formerly ZIOPHARM Oncology) develops personalized cell therapy for solid tumors, one of the most complex and expensive areas in modern oncology. This chart illustrates how heavily the company relies on debt to fund its cutting-edge, yet high-risk, research.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Alaunos Therapeutics is developing next-generation T-cell therapies for solid tumors, one of the most complex and capital-intensive areas in oncology. This chart shows how the company finances its cutting-edge research. It compares its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Alaunos Therapeutics (formerly Ziopharm Oncology) develops personalized cell therapy for solid tumors. This is one of the most advanced and capital-intensive areas in oncology. How heavily does the company rely on debt financing? This chart of total market debt helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Alaunos Therapeutics
Alaunos Therapeutics (formerly ZIOPHARM Oncology) is a biopharmaceutical company developing cell therapies for the treatment of solid tumors. This chart shows how investors value its complex technology. The valuation reflects the high risks and long road to commercialization in the field of cell therapy.
P/E of the market segment - Oncology cell gene therapy
Alaunos Therapeutics is a clinical-stage oncology company developing personalized T-cell receptor (TCR)-based cell therapies for the treatment of solid tumors. This chart illustrates the average valuation in the cell and gene therapy sector, where investors are betting on breakthrough but high-risk approaches to cancer treatment.
P/E of the market as a whole
Alaunos Therapeutics is a clinical-stage biotech developing personalized T-cell therapy for solid tumors. This chart reflects the overall risk appetite of biotech investors. It helps us understand whether TCRT's high valuation is based on faith in its innovative platform or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alaunos Therapeutics
Alaunos Therapeutics, formerly ZIOPHARM Oncology, is developing personalized T-cell therapy for solid tumors. Their approach is based on "Sleeping Beauty" technology. This chart illustrates the investors' confidence in this innovative scientific platform and its potential to create breakthrough cancer treatments.
%20P%2FE%20Alaunos%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alaunos-Therapeutics&v=1772625493256 "Chart of the company's future (projected) P/E Alaunos Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Alaunos Therapeutics is developing personalized T-cell therapy for solid tumors. This is one of the most advanced approaches in oncology. The chart shows the average profitability expectations for the sector, helping to understand the level of investor confidence in this complex but potentially breakthrough cancer-fighting technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772625493262 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Alaunos Therapeutics is developing personalized cell therapy for cancer based on T-cell receptors. This is one of the most advanced and complex areas in oncology. This risk appetite chart is an indicator of the market's willingness to fund science- and capital-intensive approaches to cancer treatment with a very long-term perspective.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772625493263 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alaunos Therapeutics
Alaunos Therapeutics is a clinical-stage biotech company developing personalized T-cell receptor-based cancer cell therapy. Its financial performance reflects the enormous investment in research and development in this cutting-edge field. This chart shows the investment in creating a personalized treatment for each patient.
Profit of companies in the market segment - Oncology cell gene therapy
Alaunos Therapeutics is a clinical-stage biotech company developing personalized T-cell therapy for solid tumors. Its approach is based on "hunting" for cancer mutations. This chart shows the overall profitability of the oncology cell therapy sector, one of the most advanced and complex in modern medicine.
Overall market profit
Alaunos Therapeutics develops innovative cell therapies for the treatment of solid tumors. The company is at the forefront of the fight against cancer. Its value and prospects are determined by scientific progress, not the current state of the economy. The dynamics in this chart do not reflect the need for breakthrough treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alaunos Therapeutics
Alaunos Therapeutics is developing personalized T-cell therapy for solid tumors. Future profits depend on the success of its sophisticated and customized technology in clinical trials. This graph reflects the very high risks and potential for breakthroughs in one of the most advanced areas of oncology.
%20profit%20of%20the%20company%20Alaunos%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alaunos-Therapeutics&v=1772625493277 "Graph of future (projected) profit of the company Alaunos Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Alaunos Therapeutics (formerly ZIOPHARM Oncology) develops personalized T-cell therapy for solid tumors. Its approach is based on the "Sleeping Beauty" gene modification technology. This chart shows revenue projections for the cell and gene therapy sector, helping to assess the potential of Alaunos's advanced oncology platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772625493292 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Alaunos Therapeutics is a biotech company developing cell therapies for the treatment of solid tumors. Its survival and growth are entirely dependent on raising funding. This earnings expectations chart reflects the overall sentiment of investors and their willingness to invest in high-risk but potentially breakthrough scientific projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772625493294 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alaunos Therapeutics
Alaunos Therapeutics is developing personalized cell therapy for cancer based on T-cell receptors. There is no revenue at the research stage. This chart reflects investor confidence in its cutting-edge, yet complex and expensive, cancer-fighting technology.
P/S market segment - Oncology cell gene therapy
Alaunos Therapeutics is a pioneer in developing personalized T-cell therapy for solid tumors. Their approach is based on identifying patient-specific T-cells that can recognize mutations in their own tumors. This chart reflects the average revenue estimate for the sector, providing insight into the market's expectations for this cutting-edge oncology approach.
P/S of the market as a whole
Alaunos Therapeutics develops personalized cell therapy for solid tumors using a unique approach to identifying cancer targets. This chart highlights how the valuation of such companies at the forefront of oncology is based on faith in their scientific platform, which contrasts sharply with the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alaunos Therapeutics
Alaunos Therapeutics is a biotech company developing personalized T-cell therapy for solid tumors. For such an innovative clinical-stage company, valuing its future revenue is critical. It reflects investors' faith in its breakthrough technology and its long-term potential to create effective cancer treatments tailored to each patient.
%20P%2FS%20Alaunos%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alaunos-Therapeutics&v=1772625493349 "The graph of the company's future (projected) P/S Alaunos Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Alaunos Therapeutics is developing personalized T-cell therapy for solid tumors. This chart compares the company's estimated future sales with expectations for the biotech sector. It shows how investors view its innovative approach to creating personalized cancer treatments and the potential of its Sleeping Beauty platform.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772625493365 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Alaunos Therapeutics is developing personalized cell therapy for cancer based on T-cell receptors that target mutations in patients' tumors. This approach is highly complex but potentially revolutionary. This chart of overall market expectations reflects investor confidence in the future of personalized oncology, despite the enormous scientific and financial risks.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772625493366 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alaunos Therapeutics
The chart shows the financial activity of Alaunos Therapeutics, a biotechnology company developing personalized cell therapy for the treatment of solid tumors. Currently in clinical trials, the company has no commercial revenue and is funded through raised capital.
Sales of companies in the market segment - Oncology cell gene therapy
Alaunos Therapeutics (formerly ZIOPHARM Oncology) is a cancer cell therapy company. It develops personalized treatments that target unique mutations in patients' tumors. While in the clinical stage, it has no revenue yet, but its technology represents the cutting edge in the fight against cancer.
Overall market sales
Alaunos Therapeutics develops innovative T-cell therapies for the treatment of solid tumors. The company is at the forefront of the fight against cancer. This general economics chart bears no relation to Alaunos's prospects, which are determined solely by scientific breakthroughs and clinical trial successes.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alaunos Therapeutics
Alaunos Therapeutics is developing personalized T-cell therapy for solid tumors. Its approach utilizes a patient's own T cells to attack cancer. Future revenues are dependent on the success of this cutting-edge technology. This chart reflects analyst expectations for the commercial potential of its innovative cancer treatment platform.
%20sales%20of%20the%20company%20Alaunos%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alaunos-Therapeutics&v=1772625493373 "Schedule of future (projected) sales of the company Alaunos Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Alaunos Therapeutics is developing personalized cell therapy for solid tumors. This chart shows the outlook for the oncology sector. Is a breakthrough in T-cell therapy expected to spur growth for the entire market? This chart provides an overview of the industry's overall scientific and commercial potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772625493377 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Alaunos Therapeutics develops innovative cell-based cancer treatments. This is a cutting-edge field of medicine, and the company's success depends on scientific breakthroughs and clinical trial results. The general economic cycles reflected in this chart bear no relation to the fundamental drivers and risks in this high-tech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772625493382 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alaunos Therapeutics
Alaunos Therapeutics (formerly ZIOPHARM Oncology) is developing personalized cell therapy for cancer based on T-cell receptors (TCR-T). This chart highlights the financial challenges and high cash burn typical of advanced biotech. Profitability is a distant goal, dependent on the success of its complex scientific platform in treating solid tumors.
Market segment marginality - Oncology cell gene therapy
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company developing personalized T-cell receptor-based cancer cell therapy. This chart reflects its financial position, where profitability depends on the success of its cutting-edge, yet complex and expensive, cancer treatment technology.
Market marginality as a whole
Alaunos Therapeutics develops personalized cell therapy for cancer. The company operates at the forefront of oncology, where the potential is enormous but the risks are high. This total return chart reflects investors' willingness to fund breakthrough, but very expensive and time-consuming, scientific projects.
Employees in the company, segment and market as a whole
Number of employees in the company Alaunos Therapeutics
Alaunos Therapeutics (formerly ZIOPHARM Oncology) develops personalized cell therapy for cancer. Its team of scientists is working on the complex "Sleeping Beauty" technology. This chart shows how the company manages its staff during expensive research, where progress depends on lab breakthroughs and results in small patient groups.
Share of the company's employees Alaunos Therapeutics within the market segment - Oncology cell gene therapy
Alaunos Therapeutics develops personalized T-cell therapy for solid tumors. This is one of the most complex and cutting-edge areas in oncology, requiring an elite team of scientists and biotechnologists. This chart shows the company's market share, reflecting its scientific potential and the scale of its cell therapy R&D activities.
Number of employees in the market segment - Oncology cell gene therapy
Alaunos Therapeutics develops personalized cell therapy for cancer based on T-cell receptors (TCR-T) that target mutations in individual patient tumors. The chart illustrates the company's work in the cell therapy sector. This cutting-edge approach represents the pinnacle of personalized medicine in oncology.
Number of employees in the market as a whole
Alaunos Therapeutics is a biotech company developing cell therapies for solid tumors. It's at the cutting edge of oncology. Its growth isn't a reflection of economics, but a direct consequence of research progress. Given the overall dynamics in this chart, Alaunos represents the venture sector, where jobs are being created to foster future breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alaunos Therapeutics (TCRT)
Alaunos Therapeutics works in the highly complex field of TCR-T cell therapy. This is pure R&D at the cutting edge of science. This chart shows the enormous "option" value the market is pricing in their technology. It reflects the market capitalization per scientist, which is a bet on their complex but potentially breakthrough platform.
%20of%20the%20company%20Alaunos%20Therapeutics%20(TCRT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alaunos-Therapeutics-TCRT&v=1772625493405 "Chart of market capitalization per employee (in thousands of dollars) of the company Alaunos Therapeutics (TCRT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Alaunos Therapeutics (TCRT) develops personalized cell therapy for solid tumors. In this cutting-edge field of oncology, this chart is a testament to their unique "sleeping beauty" technology. The company's high market capitalization per employee suggests investors see the potential for their approach to create effective treatments for a wide range of cancer patients.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772625493407 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Alaunos Therapeutics is developing innovative cancer cell therapy based on TCR-T cells. The company's value lies in its cutting-edge scientific platform. The graph shows a high valuation per employee, as the market sees enormous potential in a personalized approach to cancer treatment that could be effective where other methods fail.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772625493414 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alaunos Therapeutics (TCRT)
Alaunos Therapeutics is a clinical-stage biotech developing a cell therapy (TCR-T) for cancer treatment. This is a cutting-edge R&D field. This chart shows the net loss per employee. It reflects how much capital the company burns per scientist to advance this complex technology through clinical trials.
%20Chart%20Alaunos%20Therapeutics%20(TCRT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alaunos-Therapeutics-TCRT&v=1772625493416 "Company Profit Per Employee (in thousands of dollars) Chart Alaunos Therapeutics (TCRT)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Alaunos Therapeutics, Inc. is a biotechnology company focused on cancer cell therapy. In this cutting-edge yet capital-intensive field, per-employee efficiency reflects research progress. The graph shows the company's current financial return, which is important for assessing its stage of development compared to other players in the immuno-oncology field.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772625493417 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Alaunos Therapeutics (formerly ZIOPHARM) is a biotech company working in the field of TCR-T cell therapy. This is a highly complex R&D operation. This chart, showing average market efficiency, helps to understand the contrast with biotech, where a team of scientists burns through investors' capital in hopes of a breakthrough.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772625493418 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alaunos Therapeutics (TCRT)
Alaunos Therapeutics is an oncology company developing cell therapies. Like many biotech companies in this space, current revenue per employee may be nonexistent. The graph illustrates the potential: successful personalized cancer therapy could be extremely expensive, leading to astronomical revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alaunos-Therapeutics-TCRT&v=1772625493418 "Sales chart per company employee Alaunos Therapeutics (TCRT)")
Sales per employee in the market segment - Oncology cell gene therapy
Alaunos Therapeutics (TCRT) (formerly ZIOPHARM Oncology) is a clinical-stage biotech developing a cell therapy platform (TCR-T) for the treatment of solid tumors (cancer). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of Alaunos' R&D staffing efficiency.
Sales per employee for the market as a whole
Alaunos Therapeutics (TCRT) is a biotech company working at the forefront of oncology. They are developing personalized cell therapy (TCR-T) to combat solid tumors. This chart reflects their R&D status: the company invests in complex scientific research and has no commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Alaunos Therapeutics (TCRT)
Alaunos (TCRT), formerly Ziopharm, is a cancer cell therapy company with a long history of failures and strategy shifts. This chart shows the volume of bearish bets. The shorts reflect the market's belief that the company's latest attempt to develop an effective therapy is also likely to fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alaunos-Therapeutics-TCRT&v=1772625493426 "Short Shares Chart for the Company Alaunos Therapeutics (TCRT)")
Shares shorted by market segment - Oncology cell gene therapy
Alaunos Therapeutics (TCRT) is a biotech company developing personalized cell therapy (TCR-T) for the treatment of solid tumors. This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism about the risks and high costs of cell therapy.
Shares shorted by the overall market
Alaunos Therapeutics is an early-stage biotech (cell therapy). This chart illustrates the overall market pessimism. When fear dominates, investors don't buy "lottery tickets." They see a company with no revenue, a long R&D cycle, and a high risk of failure, and they prefer to divest.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alaunos Therapeutics (TCRT)
Alaunos Therapeutics (formerly ZIOPHARM) develops cell therapies for solid tumors, a highly complex area of oncology. This graph represents the "pulse" of their R&D. It "overheats" on early data when the technology appears to be a breakthrough, and "cools" when the company encounters scientific challenges.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alaunos-Therapeutics-TCRT&v=1772625493461 "RSI 14 indicator chart for the company's stock Alaunos Therapeutics (TCRT)")
RSI 14 Market Segment - Oncology cell gene therapy
Alaunos (TCRT) is a biotech company developing personalized cell therapy (TCR-T) for the treatment of solid tumors. This is an extremely complex but promising field. This chart tracks the collective sentiment in the Cell/Gene Oncotherapy sector. It shows when the entire industry is overheated by hype surrounding breakthroughs or oversold.
RSI 14 for the overall market
For Alaunos (TCRT), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TCRT (Alaunos Therapeutics)
Alaunos Therapeutics is a biotech developing a T-cell therapy (TCR) platform for the treatment of solid tumors. This chart shows the highly speculative average 12-month price target from analysts, reflecting their view of the risks and potential of this advanced but complex R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TCRT-Alaunos-Therapeutics&v=1772625493476 "A chart showing analyst consensus forecasts for the expected stock price. TCRT (Alaunos Therapeutics)")
The difference between the consensus estimate and the actual stock price TCRT (Alaunos Therapeutics)
Alaunos (TCRT) is a cutting-edge company developing live-cell therapy (TCR-T) for the treatment of solid tumors. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the current share price and the consensus target price, reflecting their view on the risks and the enormous potential of this cell therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TCRT-Alaunos-Therapeutics&v=1772625493479 "A chart showing the difference between the consensus forecast and the actual stock price. TCRT (Alaunos Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Alaunos Therapeutics is an R&D biotech company developing cell therapy (TCR-T) for the treatment of solid tumors. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire cell-based oncotherapy sector. It shows whether experts believe cell therapy will breakthrough beyond blood cancer.
Analysts' consensus forecast for the overall market share price
Alaunos Therapeutics is a biotech company working in one of the most cutting-edge and risky fields: cell therapy (TCR-T) for cancer treatment. This chart shows the overall "risk appetite." For Alaunos, whose technology requires massive investment, overall market optimism (a rising chart) is critical for funding and investor confidence in their platform.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alaunos Therapeutics
Alaunos (formerly Ziopharm) is a veteran cell therapy company. They are developing a non-viral technology (Sleeping Beauty) to arm a patient's T cells (TCR-T) to attack solid tumors (cancer). This chart is a summary of their reboot. It reflects their (very long) R&D journey, their struggle for funding, and their speculative bet on non-viral oncology.
AKIMA Market Segment Index - Oncology cell gene therapy
Alaunos Therapeutics operates in the cutting-edge but risky field of cancer gene therapy. Their success depends not only on science but also on operational efficiency. This chart provides a unique insight: it compares the company's composite index to the sector average, revealing whether Alaunos stands out among oncology pioneers or lags behind them.
The AKIM Index for the overall market
Alaunos Therapeutics is an immuno-oncology company developing TCR-T cell therapy (Sleeping Beauty). It is undergoing a strategic reassessment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how TCRT, a company exploring alternatives, stacks up against overall economic trends.
